AI-empowered Phase IV: Leverage our real-world therapy-focused AI to deepen your data understanding in non-interventional studies, like most leading pharma companies do already.
Unlocking Insights from Phase II-III Data: Engage in retrospective analysis to uncover new insights of your existing OCT and clinical data. With our network of leading research partners, we can assure top-notch, unbiased publication of results you can use for therapy differentiation.
Rich Data Inputs and Outputs: Handle large, diverse OCT and clinical datasets with ease, converting them into anonymized, standardized data paired with insightful AI reports.
Beyond Biomarkers: Our tool goes one step further than conventional biomarker quantification tools and delivers actionable insights on treatment patterns. We provide a comprehensive analysis of retinal therapy.
Our platform is tailored for retinal therapy, developed with leading research partners to deliver actionable insights. While we specialize in regulatory approval and commercialization stages, we’re happy to recommend tools for retinal fluid quantification or early-stage drug discovery (Phase I-IIa) if these better suit your needs. Together, let’s shape the future of retinal care.
Forge new paths with a dedicated partner.
Critical insights for treatment strategies in phases II-IV.
Prediction of expected treatment need over the coming 12 months.
A shared vision in retinal therapy research.
